Search Results for “EHR” – Page 17 – media

Precision editing of gut bacteria– Potential way to treat colitis

UT Southwestern Medical Center researchers have used precision editing of the bacterial populations in the gut to prevent or reduce the severity of inflammation in a mouse model of colitis.
- Source: sciencedaily
- 563
- January 5, 2018
colitis gut bacteria Researches
Top 5 Digital Health Trends——A Look Back At 2017

Digital health made big strides in 2017. With better provider workflows and more integrated core healthcare platforms, healthcare is on the brink of a disruption. As we move into 2018 and the next wave of innovation, here is a look back on the biggest stories that moved the needle in digital health this year.
- Source: forbes
- 792
- January 1, 2018
digital health Market Views
Health System CIOs Are Ready to Take mHealth to the Next Level

With some three-quarters of the nation’s health systems now having an mHealth communications strategy, CIOs are now setting their sights on integrating those platforms with clinical decision support tools, including the EHR.
- Source: mhealthintelligence
- 672
- December 25, 2017
CIO mHealth Researches
3 Amazing Advances in Pharmaceutical Drugs in 2017

As 2017 draws to a close, we look back at a year where advances in pharmaceutical drug therapies brought new hope to people from across the globe. These steps forward bring with them a sense of suspense as we wait for more ground-breaking work to be accomplished in 2018. Here is Drugdu.com’s list of medical advances that amazed.
- Source: Ddu
- 641
- December 25, 2017
Market Views pharmaceutical drugs
U.S. FDA approves new diabetes drug from Merck and Pfizer

A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration(FDA) said, adding another competitor to a growing class of treatments.
- Source: Reuters
- 685
- December 25, 2017
ertugliflozin Merk New Approvals Pfizer
The Top 3 Digital Health Trends to Watch In 2018

Digital health broke out in 2017. We saw more investment than ever before: Over $4.7 billion flowed into a record number of companies. While these record-breaking investments underscore the enthusiasm for new digital health solutions, another revolution was quietly happening just outside the spotlight.
- Source: fortune
- 614
- December 21, 2017
digital health Researches Telemedicine
Bay Area’s Medeor Therapeutics Bags $57M

Medeor Therapeutics announced it had closed on an oversubscribed Series B financing worth $57 million. The round was led by RA Capital Management. New investors included Sofinnova Ventures and 6 Dimensions Capital. They were joined by existing investors Vivo Capital and WuXi Healthcare Ventures.
- Source: Biospace
- 618
- November 28, 2017
cellular immunotherapies Market Views Series
Jardiance is the first and only oral type 2 diabetes medicine approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

New data presented today showed that Jardiance® reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease.
- Source: finance.yahoo
- 607
- November 17, 2017
cardiovascular diabetes Jardiance® peripheral artery disease
NIH accelerates the development of new cancer immunotherapy strategies for more patients

The National Institutes of Health(NIH) and 11 leading biopharmaceutical companies have launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot.
- Source: nih.gov
- 551
- October 16, 2017
Market Views NIH PACT
FDA Grants Priority Review To Gilotrif For Uncommon EGFR Mutations In Advanced NSCLC

Boehringer Ingelheim announced that the supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). The application for Gilotrif is currently under review for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 21 (L861Q), G719X or S768I substitution mutations as detected by an FDA-approved test.
- Source: careers.biospace
- 547
- October 13, 2017
EGFR New Approvals NSCLC sNDA

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.